SwitzerlandSwitzerland

OECD gives update of key biotech indicators

08.12.2010

Geneva – The Organisation for Economic Cooperation and Development (OECD) has published the latest comparable figures on the biotech branch in the US and several European countries . As expected, the US had the largest biotech branch with 3,492 biotech R&D firms (including 2,335 dedicated biotech companies, 75% thereof employing less than 50 staff), generating 41.8% of all PCT patent applications and spending $32.4bn on biotech R&D. Taken together, all 27 EU countries made 28.8% of the patent applications. As of 2008, France had the most biotech firms in Europe (1,067/676 thereof dedicated biotechs) and highest company R&D expenditure with $2.5bn, followed by Spain (942/ 305, R&D expenditure by biotechs (bex): $607m, public biotech expenditure (pbe): $1.1bn), Germany (593/501, bex: $1.2bn, pbe: $4.6bn), Switzerland (288/184, bex: $922m), The Netherlands (206/72, bex: $396m, pbe: $138m), Italy (197/117, bex: $360m, pbe: $94m), Ireland (167/71, bex: $302m), Norway (161/n.n., bex: $127m, pbe: $154m), Belgium 145/122 bex: $574m), Finland (141/77), Denmark (124/79, bex: $492m, pbe: $182m), Austria (121/111), Portugal (120/55 bex: $32m, pbe: $32m), the Czech Republic (93/69 bex: $51m, pbe: $88m), Estonia (30/25 bex: $12.7m), Poland (21/11 bex: $9.9m, pbe: $181m), Slovak Republic (11/8 bex: $2.4m, pbe: $12.6m), and Slovenia (10/3 bex: $20.7m, pbe: $3.4m). Biotech R&D intensity was highest in Denmark (0.43%), Switzerland (0.38%), and the US (0.37%). While most biotechs (>60%) were small (less then 50 staff), most biotechnology R&D was undertaken by larger biotechnology firms. Several countries could not meet the OECD deadline and will be included next year: Belgium, Sweden and the UK.

SwitzerlandSwitzerland

21.02.2012

Basel/Berkeley – Europe enters into the age of personalised medicine. The European Commission has approved the melanoma drug Zelboraf. While the compound was developed by US-based Plexxikon Inc., owned by Daiichi Sankyo Group,...

SwitzerlandSwitzerland

26.01.2012

Basel – The rumours started just before Christmas. Roche wants Illumina. Just how dearly, has just become clear. The Swiss drugmaker made a $5.7b hostile bid for Illumina, the current market leader in Next-Generation sequencing....

SwitzerlandSwitzerland

23.01.2012

Basel – Good and bad news for Swiss drugmaker Novartis. First a look on the bright side: Signifor, for the treatment of Cushing's disease, is on its final stretch to approval. The Committee for Medicinal Products for Human Use...

SwitzerlandSwitzerland

19.12.2011

Basel - It is a further push for Roche's ambitions in medicine concerning the treatment of skin cancer: The European Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug Zelboraf and its companion...

SwitzerlandSwitzerland

17.12.2011

Allschwil – Europe’s largest stand-alone biotech company Actelion Ltd. is receiving an injection of fresh capital. Under the guidance of the two biggest Swiss banks – UBS and Credit Suisse – the Swiss company will be issued a...

SwitzerlandSwitzerland

14.12.2011

Stans – Due to the current financial market conditions and the lack of significant progress with currently available options, Swiss drug developer Mondobiotech says it will be implementing restructuring measures. Together with...

SwitzerlandSwitzerland

14.12.2011

Geneva – There's is life in Swiss biotechnology beyond big pharma. Genentech has launched a First-in-Human study with anti-IL-17, an antibody made by the Swiss biotechnology company NovImmune. The fully human monoclonal antibody,...

SwitzerlandSwitzerland

22.11.2011

Basel – The FDA has withdrawn the accelerated approval for Roche's Avastin (bevacizumab) to treat metastasising breast cancer. The US regulatory authority had originally granted accelerated approval for Avastin's use in treating...

SwitzerlandSwitzerland

16.11.2011

Basel/Hervel – It may be the end of Novartis' lucky streak in osteoporosis. While the once a year osteoporosis injection Aclasta (a bisphosphonate) sells well, the Swiss pharma company had to break disastrous news from a...

Displaying results 11 to 20 out of 276

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/browse/1/article/oecd-gives-update-of-key-biotech-indicators.html

Image Gallery

Stock list

All quotes

TOP

  • CYTOS (CH)0.23 CHF53.3%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • CO.DON (D)3.40 EUR9.7%

FLOP

  • WILEX (D)0.88 EUR-15.4%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • FLAMEL TECHNOLOGIES (F)11.01 USD-13.5%

TOP

  • CO.DON (D)3.40 EUR91.0%
  • WILEX (D)0.88 EUR51.7%
  • BIOTECH PHARMACON (N)17.50 NOK50.9%

FLOP

  • CYTOS (CH)0.23 CHF-92.0%
  • BIONOR PHARMA (N)2.11 NOK-47.9%
  • GW PHARMACEUTICALS (UK)219.50 GBP-46.5%

TOP

  • SILENCE THERAPEUTICS (UK)255.00 GBP5900.0%
  • IXICO (UK)69.50 GBP776.4%
  • PLETHORA (UK)11.00 GBP609.7%

FLOP

  • CYTOS (CH)0.23 CHF-94.7%
  • EVOCUTIS (UK)0.22 GBP-92.9%
  • AGENNIX (D)0.04 EUR-78.9%

No liability assumed, Date: 15.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

Frankfurt am Main

7th DVFA Life Science Conference

White Paper